recombinant mouse leptin (Novoprotein)
Structured Review

Recombinant Mouse Leptin, supplied by Novoprotein, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant mouse leptin/product/Novoprotein
Average 86 stars, based on 1 article reviews
Images
1) Product Images from "Leptin From Fibro‐Adipogenic Progenitor Cells (FAPs) Regulates Masseter Muscle Disuse Atrophy and Ectopic Fat Accumulation"
Article Title: Leptin From Fibro‐Adipogenic Progenitor Cells (FAPs) Regulates Masseter Muscle Disuse Atrophy and Ectopic Fat Accumulation
Journal: Journal of Cachexia, Sarcopenia and Muscle
doi: 10.1002/jcsm.70141
Figure Legend Snippet: Leptin deficiency as a potential cause of ectopic fat accumulation and muscle atrophy in the masseter muscle. (a) LEPR and leptin bands and quantitative analysis in whole muscle extracts from masseter muscles on the extraction side of mice. GADPH was used as a loading control (one‐way ANOVA; n = 3). (b) Experimental flow chart. (c) Representative images of Oil Red O staining of the mouse masseter muscle and triglyceride (TG) content of mouse masseter muscle (scale bar, 100 μm; one‐way ANOVA; n = 3). (d) LEPR, MuRF‐1 and MAFbx bands and quantitative analysis in whole muscle extracts of mouse masseter muscle (GADPH was used as a loading control) and images of immunohistochemical staining (MuRF‐1 and MAFbx) of the masseter muscle on the extracted side of mice and quantitative analysis of the positive area (brown colour) (scale bar, 100 μm; one‐way ANOVA; n = 3). (e) H&E staining images of masseter muscle on the extraction side of mice and quantitative analysis of the mean cross‐sectional area of muscle fibres (scale bar, 100 μm; one‐way ANOVA; n = 3). (f) Mouse body weight, mean food intake, fasting blood glucose, serum insulin, serum TG and serum free fatty acids (one‐way ANOVA; n = 3). *p < 0.05, **p < 0.01, ***p < 0.001; error line, mean ± standard value. DA: disuse atrophy Week 8; DA + Lep: DA + exogenous leptin treatment Week 8; NC: negative control.
Techniques Used: Muscles, Extraction, Control, Staining, Immunohistochemical staining, Negative Control
Figure Legend Snippet: RNA‐seq reveals leptin restores downregulation of the PPARα/PPAR signalling pathway in the wasted atrophic masseter muscle. (a) Bubble plots of KEGG enrichment analysis in normal masseter muscle and atrophied masseter muscle. The significance thresholds of the pathways in the graphs all satisfy p < 0.05. (b) GSEA image of the PPARα signalling pathway. (c) Clustering heatmap of differentially expressed genes in lipid metabolism and cytokine‐related pathways in normal masseter muscle and atrophic bite muscle (data are normalized values). (d) qRT‐PCR analysis of PPARα (one‐way ANOVA; n = 3). (e) PPARα bands in whole muscle extracts of mouse masseter muscle (Lamin B1 was used as a loading control) and quantitative analysis (one‐way ANOVA; n = 3). *p < 0.05, **p < 0.01, ***p < 0.001; error line, mean ± standard deviation. DA: disuse atrophy Week 8; DA + Lep: DA + exogenous leptin treatment Week 8; NC: negative control.
Techniques Used: RNA Sequencing, Quantitative RT-PCR, Control, Standard Deviation, Negative Control
Figure Legend Snippet: Leptin enhances mitochondrial FA β‐oxidation in C2C12 myotubes by directly activating PPARα, consequently attenuating intracellular lipid accumulation. (a) Oil Red stained images of C2C12 myotubes and triglyceride content (scale bar, 50 μm; one‐way ANOVA; n = 3). (b) MuRF‐1 and MAFbx bands and quantitative analysis (one‐way ANOVA; n = 3). (c) PPARα bands and quantitative analysis (one‐way ANOVA; n = 3). (d) Oil Red stained images of C2C12 myotubes and triglyceride content (scale bar, 50 μm; one‐way ANOVA; n = 3). (e) MuRF‐1, MAFbx and PPARα bands and quantitative analysis (one‐way ANOVA; n = 3). (f) CPT‐1a, ACOX1, CD36, FABP3 and SREBP‐1 bands and quantitative analysis (one‐way ANOVA; n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001; error line, mean ± standard deviation. Lep, leptin‐treated group; NC, negative control group (cultured in normal medium); PA, palmitic acid‐treated group; PA + Lep, palmitic acid combined with leptin‐treated group; PA + Lep + siPPARα, palmitic acid, Leptin and PPARα siRNA co‐treatment group; PA + siPPARα: palmitic acid‐treated combined with PPARα siRNA transfection group.
Techniques Used: Staining, Standard Deviation, Negative Control, Cell Culture, Transfection
Figure Legend Snippet: FAPs are a source of localized leptin in the masseter muscle. (a) ELISA assay of serum leptin levels in mice. No significant difference (one‐way ANOVA; n = 4). (b) Images of mouse masseter muscle immunofluorescence staining (leptin) and quantitative analysis (scale bar, 100 μm; one‐way ANOVA; n = 3). (c) Immunofluorescence staining images and quantitative analysis of leptin and FAPs in mouse masseter muscle (scale bar, 100 μm; one‐way ANOVA; n = 3). (d) Histological assessment of mouse masseter muscle sections showing leptin immunoreactivity co‐localized with FAPs. (Right: white arrows). Scale bar = 100 μm (left); scale bar = 10 μm (right). (e) FACS of FAPs. (f) qRT‐PCR and ELISA analysis of leptin (one‐way ANOVA; n = 3). *p < 0.05, **p < 0.01, ***p < 0.001; error line, mean ± standard deviation. 0, 2, 4, 6 and 8 weeks: 0, 2, 4, 6 and 8 weeks after unilateral molar extraction.
Techniques Used: Enzyme-linked Immunosorbent Assay, Immunofluorescence, Staining, Quantitative RT-PCR, Standard Deviation, Extraction
Figure Legend Snippet: Nilotinib induces apoptosis in masseter muscle FAPs. (a) Experimental flow chart. (b) Effect of continuous injection of nilotinib (25 mg/kg/d ip.) on masseter muscle FAPs apoptosis on Days 3 and 5 in disuse atrophy mice, proportion of apoptotic FAPs cells and quantification of FAPs cells (scale bar, 50 μm; one‐way ANOVA; n = 3). (c) Images of masseter muscle immunofluorescence staining and quantitative analysis of leptin and PDGFRα co‐localization (scale bar, 100 μm; one‐way ANOVA; n = 3). **p < 0.01, ***p < 0.001. DA: disuse atrophy Week 4; DA + Lep: disuse atrophy Week 4 + 5 days of nilo injection; NC: negative control; nilo: negative control +5 days of nilo injection.
Techniques Used: Injection, Immunofluorescence, Staining, Negative Control
Figure Legend Snippet: Increased ectopic fat accumulation and wasting atrophy after induction of apoptosis in FAPs cells. (a) Representative images of Oil Red O staining of the mouse masseter muscle (scale bar, 100 μm). (b) Triglyceride (TG) content of mouse masseter muscle (one‐way ANOVA; n = 3). (c) Leptin, MuRF‐1 and MAFbx bands in whole muscle extracts of mouse masseter muscle and quantitative analysis. GADPH was used as a control for up‐sampling. (d) H&E staining images of masseter muscle on the extracted side of mice and quantitative analysis of the mean cross‐sectional area of muscle fibres (scale bar, 100 μm; one‐way ANOVA; n = 3). (e) Images of immunohistochemical staining (MuRF‐1 and MAFbx) of the masseter muscle on the extracted side of mice and quantitative analysis of the positive area (brown colour) (scale bar, 100 μm; one‐way ANOVA; n = 3). *p < 0.05, **p < 0.01, ***p < 0.001; error line, mean ± standard deviation. DA: disuse atrophy Week 4; DA + Lep: disuse atrophy Week 4 + 5‐day nilo injection; NC: negative control; nilo: negative control + 5‐day nilo injection.
Techniques Used: Staining, Control, Sampling, Immunohistochemical staining, Standard Deviation, Injection, Negative Control

